首页 > 最新文献

Gastroenterology Research最新文献

英文 中文
Development of a Predictive Model for Common Bile Duct Stones in Patients With Clinical Suspicion of Choledocholithiasis: A Cohort Study. 临床怀疑胆总管结石患者胆总管结石预测模型的建立:一项队列研究。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-19 DOI: 10.14740/gr1560
Suppadech Tunruttanakul, Kotchakorn Verasmith, Jayanton Patumanond, Chatchai Mingmalairak

Background: Current choledocholithiasis guidelines heavily focus on patients with low or no risk, they may be inappropriate for populations with high rates of choledocholithiasis. We aimed to develop a predictive scoring model for choledocholithiasis in patients with relevant clinical manifestations.

Methods: A multivariable predictive model development study based on a retrospective cohort of patients with clinical suspicion of choledocholithiasis was used in this study. The setting was a 700-bed public tertiary hospital. Participants were patients who had completed three reference tests (endoscopic retrograde cholangiography, magnetic resonance cholangiopancreatography, and intraoperative cholangiography) from January 2019 to June 2021. The model was developed using logistic regression analysis. Predictor selection was conducted using a backward stepwise approach. Three risk groups were considered. Model performance was evaluated by area under the receiver operating characteristic curve, calibration, classification measures, and decision curve analyses.

Results: Six hundred twenty-one patients were included; the choledocholithiasis prevalence was 59.9%. The predictors were age > 55 years, pancreatitis, cholangitis, cirrhosis, alkaline phosphatase level of 125 - 250 or > 250 U/L, total bilirubin level > 4 mg/dL, common bile duct size > 6 mm, and common bile duct stone detection. Pancreatitis and cirrhosis each had a negative score. The sum of scores was -4.5 to 28.5. Patients were categorized into three risk groups: low-intermediate (score ≤ 5), intermediate (score 5.5 - 14.5), and high (score ≥ 15). Positive likelihood ratios were 0.16 and 3.47 in the low-intermediate and high-risk groups, respectively. The model had an area under the receiver operating characteristic curve of 0.80 (95% confidence interval: 0.76, 0.83) and was well-calibrated; it exhibited better statistical suitability to the high-prevalence population, compared to current guidelines.

Conclusions: Our scoring model had good predictive ability for choledocholithiasis in patients with relevant clinical manifestations. Consideration of other factors is necessary for clinical application, particularly regarding the availability of expert physicians and specialized equipment.

背景:目前的胆总管结石指南主要侧重于低风险或无风险的患者,它们可能不适合胆总管结石高发人群。我们的目的是为有相关临床表现的胆总管结石患者建立一个预测评分模型。方法:基于临床疑似胆总管结石患者的回顾性队列,采用多变量预测模型开发研究。事发地点是一家拥有700张床位的公立三级医院。参与者是在2019年1月至2021年6月期间完成了三次参考检查(内窥镜逆行胆管造影、磁共振胆管造影术和术中胆管造影)的患者。该模型采用logistic回归分析。预测因子选择采用后向逐步方法。考虑了三个风险群体。通过受试者工作特征曲线下的面积、校准、分类措施和决策曲线分析来评估模型的性能。结果:共纳入621例患者;胆总管结石患病率为59.9%。预测因素为年龄> 55岁、胰腺炎、胆管炎、肝硬化、碱性磷酸酶水平125 - 250或> 250 U/L、总胆红素水平> 4 mg/dL、总胆管尺寸> 6 mm、总胆管结石检测。胰腺炎和肝硬化的评分均为阴性。总分在-4.5到28.5之间。患者分为中低危组(评分≤5)、中危组(评分5.5 ~ 14.5)和高危组(评分≥15)。低、中、高危组的阳性似然比分别为0.16和3.47。该模型的受试者工作特征曲线下面积为0.80(95%置信区间:0.76,0.83),校准良好;与现行指南相比,它对高患病率人群表现出更好的统计适用性。结论:我们的评分模型对有相关临床表现的胆总管结石患者有较好的预测能力。临床应用需要考虑其他因素,特别是关于专家医生和专业设备的可用性。
{"title":"Development of a Predictive Model for Common Bile Duct Stones in Patients With Clinical Suspicion of Choledocholithiasis: A Cohort Study.","authors":"Suppadech Tunruttanakul,&nbsp;Kotchakorn Verasmith,&nbsp;Jayanton Patumanond,&nbsp;Chatchai Mingmalairak","doi":"10.14740/gr1560","DOIUrl":"https://doi.org/10.14740/gr1560","url":null,"abstract":"<p><strong>Background: </strong>Current choledocholithiasis guidelines heavily focus on patients with low or no risk, they may be inappropriate for populations with high rates of choledocholithiasis. We aimed to develop a predictive scoring model for choledocholithiasis in patients with relevant clinical manifestations.</p><p><strong>Methods: </strong>A multivariable predictive model development study based on a retrospective cohort of patients with clinical suspicion of choledocholithiasis was used in this study. The setting was a 700-bed public tertiary hospital. Participants were patients who had completed three reference tests (endoscopic retrograde cholangiography, magnetic resonance cholangiopancreatography, and intraoperative cholangiography) from January 2019 to June 2021. The model was developed using logistic regression analysis. Predictor selection was conducted using a backward stepwise approach. Three risk groups were considered. Model performance was evaluated by area under the receiver operating characteristic curve, calibration, classification measures, and decision curve analyses.</p><p><strong>Results: </strong>Six hundred twenty-one patients were included; the choledocholithiasis prevalence was 59.9%. The predictors were age > 55 years, pancreatitis, cholangitis, cirrhosis, alkaline phosphatase level of 125 - 250 or > 250 U/L, total bilirubin level > 4 mg/dL, common bile duct size > 6 mm, and common bile duct stone detection. Pancreatitis and cirrhosis each had a negative score. The sum of scores was -4.5 to 28.5. Patients were categorized into three risk groups: low-intermediate (score ≤ 5), intermediate (score 5.5 - 14.5), and high (score ≥ 15). Positive likelihood ratios were 0.16 and 3.47 in the low-intermediate and high-risk groups, respectively. The model had an area under the receiver operating characteristic curve of 0.80 (95% confidence interval: 0.76, 0.83) and was well-calibrated; it exhibited better statistical suitability to the high-prevalence population, compared to current guidelines.</p><p><strong>Conclusions: </strong>Our scoring model had good predictive ability for choledocholithiasis in patients with relevant clinical manifestations. Consideration of other factors is necessary for clinical application, particularly regarding the availability of expert physicians and specialized equipment.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 5","pages":"240-252"},"PeriodicalIF":1.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/78/gr-15-240.PMC9635785.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40717667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Rates, Reasons, and Independent Predictors of Readmissions in Portal Venous Thrombosis Hospitalizations in the USA. 美国门静脉血栓再入院的比率、原因和独立预测因素。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-19 DOI: 10.14740/gr1561
Robert Kwei-Nsoro, Pius Ojemolon, Hisham Laswi, Ebehiwele Ebhohon, Abdultawab Shaka, Wasey Ali Mir, Abdul Hassan Siddiqui, Jobin Philipose, Hafeez Shaka

Background: Portal vein thrombosis (PVT), generally considered rare, is becoming increasingly recognized with advanced imaging. Limited data exist regarding readmissions in PVT and its burden on the overall healthcare cost. This study aimed to outline the burden of PVT readmissions and identify the modifiable predictors of readmissions.

Methods: The National Readmission Database (NRD) was used to identify PVT admissions from 2016 to 2019. Using the patient demographic and hospital-specific variables within the NRD, we grouped patient encounters into two cohorts, 30- and 90-day readmission cohorts. We assessed comorbidities using the validated Elixhauser comorbidity index. We obtained inpatient mortality rates, mean length of hospital stay (LOS), total hospital cost (THC), and causes of readmissions in both 30- and 90-day readmission cohorts. Using a multivariate Cox regression analysis, we identified the independent predictors of 30-day readmissions.

Results: We identified 17,971 unique index hospitalizations, of which 2,971 (16.5%) were readmitted within 30 days. The top five causes of readmissions in both 30-day and 90-day readmission cohorts were PVT, sepsis, hepatocellular cancer, liver failure, and alcoholic liver cirrhosis. The following independent predictors of 30-day readmission were identified: discharge against medical advice (AMA) (adjusted hazard ratio (aHR) 1.86; P = 0.002); renal failure (aHR 1.44, P = 0.014), metastatic cancer (aHR 1.31, P = 0.016), fluid and electrolyte disorders (aHR 1.20, P = 0.004), diabetes mellitus (aHR 1.31, P = 0.001) and alcohol abuse (aHR 1.31, P ≤ 0.001).

Conclusion: The readmission rate identified in this study was higher than the national average and targeted interventions addressing these factors may help reduce the overall health care costs.

背景:门静脉血栓形成(PVT)通常被认为是罕见的,随着先进的影像学越来越被认识到。关于PVT再入院及其对总体医疗成本负担的数据有限。本研究旨在概述PVT再入院的负担,并确定再入院的可修改预测因素。方法:使用国家再入院数据库(NRD)对2016年至2019年的PVT入院情况进行识别。使用NRD中的患者人口统计学和医院特定变量,我们将患者分组为两个队列,30天和90天再入院队列。我们使用Elixhauser合并症指数评估合并症。在30天和90天的再入院队列中,我们获得了住院死亡率、平均住院时间(LOS)、总住院费用(THC)和再入院原因。使用多变量Cox回归分析,我们确定了30天再入院的独立预测因素。结果:我们确定了17971例独特指数住院,其中2971例(16.5%)在30天内再次入院。在30天和90天的再入院队列中,再入院的前五大原因是PVT、败血症、肝细胞癌、肝功能衰竭和酒精性肝硬化。确定了以下30天再入院的独立预测因素:不遵医嘱出院(调整风险比(aHR) 1.86;P = 0.002);肾衰竭(aHR 1.44, P = 0.014)、转移性癌症(aHR 1.31, P = 0.016)、体液和电解质紊乱(aHR 1.20, P = 0.004)、糖尿病(aHR 1.31, P = 0.001)和酗酒(aHR 1.31, P≤0.001)。结论:本研究确定的再入院率高于全国平均水平,针对这些因素的有针对性的干预措施可能有助于降低总体卫生保健成本。
{"title":"Rates, Reasons, and Independent Predictors of Readmissions in Portal Venous Thrombosis Hospitalizations in the USA.","authors":"Robert Kwei-Nsoro,&nbsp;Pius Ojemolon,&nbsp;Hisham Laswi,&nbsp;Ebehiwele Ebhohon,&nbsp;Abdultawab Shaka,&nbsp;Wasey Ali Mir,&nbsp;Abdul Hassan Siddiqui,&nbsp;Jobin Philipose,&nbsp;Hafeez Shaka","doi":"10.14740/gr1561","DOIUrl":"https://doi.org/10.14740/gr1561","url":null,"abstract":"<p><strong>Background: </strong>Portal vein thrombosis (PVT), generally considered rare, is becoming increasingly recognized with advanced imaging. Limited data exist regarding readmissions in PVT and its burden on the overall healthcare cost. This study aimed to outline the burden of PVT readmissions and identify the modifiable predictors of readmissions.</p><p><strong>Methods: </strong>The National Readmission Database (NRD) was used to identify PVT admissions from 2016 to 2019. Using the patient demographic and hospital-specific variables within the NRD, we grouped patient encounters into two cohorts, 30- and 90-day readmission cohorts. We assessed comorbidities using the validated Elixhauser comorbidity index. We obtained inpatient mortality rates, mean length of hospital stay (LOS), total hospital cost (THC), and causes of readmissions in both 30- and 90-day readmission cohorts. Using a multivariate Cox regression analysis, we identified the independent predictors of 30-day readmissions.</p><p><strong>Results: </strong>We identified 17,971 unique index hospitalizations, of which 2,971 (16.5%) were readmitted within 30 days. The top five causes of readmissions in both 30-day and 90-day readmission cohorts were PVT, sepsis, hepatocellular cancer, liver failure, and alcoholic liver cirrhosis. The following independent predictors of 30-day readmission were identified: discharge against medical advice (AMA) (adjusted hazard ratio (aHR) 1.86; P = 0.002); renal failure (aHR 1.44, P = 0.014), metastatic cancer (aHR 1.31, P = 0.016), fluid and electrolyte disorders (aHR 1.20, P = 0.004), diabetes mellitus (aHR 1.31, P = 0.001) and alcohol abuse (aHR 1.31, P ≤ 0.001).</p><p><strong>Conclusion: </strong>The readmission rate identified in this study was higher than the national average and targeted interventions addressing these factors may help reduce the overall health care costs.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 5","pages":"253-262"},"PeriodicalIF":1.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/51/gr-15-253.PMC9635786.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40717663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Adult Intussusception in Chronic Marijuana Users. 慢性大麻使用者的成人肠套叠。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-19 DOI: 10.14740/gr1554
Jiten P Kothadia, Anwesh Dash, Rajanshu Verma, Kyle Kreitman, Peter D Snell, Mohammad K Ismail

Intussusception is common in children, but it is rare in adults. The most common causes of adult intussusception (AI) are due to a pathological lead point with a common etiology being malignancy. Intra-luminal irritants should be considered the possible etiology of intussusception in patients without a pathological lead point. Marijuana use has increased dramatically in the United States over the last decade. With increasing public acceptance and legalization of marijuana, various adverse side effects have become more prominent. Marijuana has been shown to disrupt gastrointestinal tract motility by inhibiting cholinergic mechanisms. Here we describe four cases of AI who are chronic marijuana users. This well-referenced review gives attention to the harmful effects of marijuana, given the increasing use of marijuana and its derivatives in the United States.

肠套叠在儿童中很常见,但在成人中很少见。成人肠套叠(AI)最常见的原因是由于一个病理先导点,常见的病因是恶性肿瘤。在没有病理线索的患者中,应考虑肠套叠可能的病因。在过去的十年里,大麻的使用在美国急剧增加。随着公众对大麻的接受度和合法化程度的提高,大麻的各种不良副作用也越来越突出。大麻已被证明通过抑制胆碱能机制扰乱胃肠道运动。在这里,我们描述了四个长期吸食大麻的人工智能案例。鉴于大麻及其衍生物在美国的使用日益增加,这篇引用广泛的评论关注了大麻的有害影响。
{"title":"Adult Intussusception in Chronic Marijuana Users.","authors":"Jiten P Kothadia,&nbsp;Anwesh Dash,&nbsp;Rajanshu Verma,&nbsp;Kyle Kreitman,&nbsp;Peter D Snell,&nbsp;Mohammad K Ismail","doi":"10.14740/gr1554","DOIUrl":"https://doi.org/10.14740/gr1554","url":null,"abstract":"<p><p>Intussusception is common in children, but it is rare in adults. The most common causes of adult intussusception (AI) are due to a pathological lead point with a common etiology being malignancy. Intra-luminal irritants should be considered the possible etiology of intussusception in patients without a pathological lead point. Marijuana use has increased dramatically in the United States over the last decade. With increasing public acceptance and legalization of marijuana, various adverse side effects have become more prominent. Marijuana has been shown to disrupt gastrointestinal tract motility by inhibiting cholinergic mechanisms. Here we describe four cases of AI who are chronic marijuana users. This well-referenced review gives attention to the harmful effects of marijuana, given the increasing use of marijuana and its derivatives in the United States.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 5","pages":"278-283"},"PeriodicalIF":1.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/22/1f/gr-15-278.PMC9635787.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40717665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of Percutaneous Endoscopic Gastrostomy Placement in Patients With SARS-CoV-2 Infection. 经皮内镜胃造口术在SARS-CoV-2感染患者中的安全性
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-10-01 Epub Date: 2022-10-19 DOI: 10.14740/gr1533
Ayushi Shah, Zunirah Ahmed, Fadl Zeineddine, Eamonn M M Quigley
Background Coronavirus disease 2019 (COVID-19) can lead to ventilator-dependent chronic respiratory failure and a need for tube feeding. Percutaneous endoscopic gastrostomy (PEG) placement provides more sustainable longer-term enteral access with fewer side effects compared to the long-term nasogastric tube placement. Bleeding is a recognized complication of PEG placement, and many COVID-19 patients are on antiplatelets/anticoagulants, yet minimal data exist on the safety of PEG tube placement in this context. Methods A retrospective chart review identified patients who underwent PEG placement between January 2020 and January 2021 at a single institution. Success was defined as PEG placement and use to provide enteral nutrition with no complications requiring removal within 4 weeks. Results Thirty-six patients with and 104 age- and sex-matched patients without COVID-19 infection were included. More COVID-19 patients were obese, on anticoagulants, had low serum albumin levels and had a tracheostomy in place. Of those patients, 8.3% with COVID-19 developed PEG-related complications compared to 16.3% without (P = 0.28). PEG success rates in patients with and without COVID-19 were similar at 97.2% and 92.3%, respectively (P = 0.44). Conclusion PEG tube placement is comparatively safe in COVID-19 patients who need long-term enteral access.
背景:2019冠状病毒病(COVID-19)可导致依赖呼吸机的慢性呼吸衰竭,需要管饲。与长期鼻胃管置入相比,经皮内镜胃造口术(PEG)置入提供了更可持续的长期肠内通路,副作用更少。出血是公认的PEG置入并发症,许多COVID-19患者正在使用抗血小板/抗凝剂,但在这种情况下,关于PEG管置入安全性的数据很少。方法:回顾性分析了2020年1月至2021年1月在同一家机构接受PEG植入的患者。成功的定义是PEG放置和使用提供肠内营养,没有并发症需要在4周内移除。结果:纳入36例感染患者和104例年龄和性别匹配的未感染COVID-19患者。更多的COVID-19患者肥胖,服用抗凝血剂,血清白蛋白水平低,并进行了气管切开术。在这些患者中,8.3%的COVID-19患者出现了peg相关并发症,而没有出现peg相关并发症的患者为16.3% (P = 0.28)。合并和未合并COVID-19患者的PEG成功率相似,分别为97.2%和92.3% (P = 0.44)。结论:对于需要长期肠内通路的COVID-19患者,置PEG管是相对安全的。
{"title":"Safety of Percutaneous Endoscopic Gastrostomy Placement in Patients With SARS-CoV-2 Infection.","authors":"Ayushi Shah,&nbsp;Zunirah Ahmed,&nbsp;Fadl Zeineddine,&nbsp;Eamonn M M Quigley","doi":"10.14740/gr1533","DOIUrl":"https://doi.org/10.14740/gr1533","url":null,"abstract":"Background Coronavirus disease 2019 (COVID-19) can lead to ventilator-dependent chronic respiratory failure and a need for tube feeding. Percutaneous endoscopic gastrostomy (PEG) placement provides more sustainable longer-term enteral access with fewer side effects compared to the long-term nasogastric tube placement. Bleeding is a recognized complication of PEG placement, and many COVID-19 patients are on antiplatelets/anticoagulants, yet minimal data exist on the safety of PEG tube placement in this context. Methods A retrospective chart review identified patients who underwent PEG placement between January 2020 and January 2021 at a single institution. Success was defined as PEG placement and use to provide enteral nutrition with no complications requiring removal within 4 weeks. Results Thirty-six patients with and 104 age- and sex-matched patients without COVID-19 infection were included. More COVID-19 patients were obese, on anticoagulants, had low serum albumin levels and had a tracheostomy in place. Of those patients, 8.3% with COVID-19 developed PEG-related complications compared to 16.3% without (P = 0.28). PEG success rates in patients with and without COVID-19 were similar at 97.2% and 92.3%, respectively (P = 0.44). Conclusion PEG tube placement is comparatively safe in COVID-19 patients who need long-term enteral access.","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 5","pages":"263-267"},"PeriodicalIF":1.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c3/2b/gr-15-263.PMC9635784.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40717666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proton Pump Inhibitors Use and Increased Risk of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Retrospective Cohort Analysis. 肝硬化患者使用质子泵抑制剂和增加自发性细菌性腹膜炎风险:一项回顾性队列分析。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-08-01 Epub Date: 2022-08-23 DOI: 10.14740/gr1545
Loai Dahabra, Malek Kreidieh, Mohammad Abureesh, Ahmad Abou Yassine, Liliane Deeb
<p><strong>Background: </strong>Since their introduction in the early 1980s, proton pump inhibitors (PPIs) have been used worldwide for a broad range of indications. Unfortunately, however, PPIs have become overly prescribed by healthcare providers, sometimes in the absence of clear indications. Although PPIs were initially presumed to have an excellent safety profile, emerging studies have shed light on the association between their long-term use and a myriad of side effects, including the possibility of an increased risk of spontaneous bacterial peritonitis (SBP). Data available to date regarding the association between PPI use and SBP development in cirrhotic patients is conflicting. While some observational studies provide no association between PPI use in cirrhotic patients and an increased risk of SBP development, many others support this association. As a result of the conflicting conclusions from case controls, cohorts, and meta-analyses, we aimed to carry out this retrospective cohort analysis of data from cirrhotic patients included in the electronic medical record-based commercial database, EXPLORYS (IMB-WATSON, Cleveland, Ohio). Our aim was to evaluate for a possible association between PPIs use and the risk of SBP development in cirrhotic patients and to compare the prevalence of SBP development between cirrhotic patients who were actively using PPIs and those who were not.</p><p><strong>Methods: </strong>A retrospective cohort analysis with chart review was conducted on patients with cirrhosis who were included in the electronic medical record-based commercial database, EXPLORYS (IMB-WATSON, Cleveland, Ohio). Using this database, records were reviewed between December 2017 and 2020. Included patients were adults aged 30 to 79 years with a Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT) diagnosis of liver cirrhosis. Included patients with a SNOMED-CT diagnosis of liver cirrhosis were divided into two groups: the first group included all cirrhotic patients who did not use PPIs and the second group included all cirrhotic patients who were on PPIs at home.</p><p><strong>Results: </strong>In our analysis, SBP occurred in 1.7% (1,860 patients) of the included cirrhotic patients whether they were actively taking PPIs or not. Among the 40,670 cirrhotic patients who were on PPIs at home, 1,350 (3.3%) patients developed SBP. On multivariate analysis, PPI use was the strongest predictor for SBP in cirrhotic patients (odds ratio (OR) = 4.24; 95% confidence interval (CI): 3.83 - 4.7, P value < 0.0001), with cirrhotic patients taking PPIs being 4.24 more likely to develop SBP than those not on PPIs. In addition, PPI use, history of bleeding varices, age, race, and gender were found to be independent predicting factors for SBP, in descending order of importance.</p><p><strong>Conclusions: </strong>Our retrospective cohort analysis has shown that the use of PPIs in patients with liver cirrhosis is an independent predicting risk fac
背景:质子泵抑制剂(PPIs)自20世纪80年代初问世以来,已在世界范围内广泛用于适应症。然而,不幸的是,PPIs被医疗保健提供者过度开处方,有时在缺乏明确适应症的情况下。虽然PPIs最初被认为具有良好的安全性,但新兴的研究已经阐明了长期使用PPIs与无数副作用之间的关系,包括自发性细菌性腹膜炎(SBP)风险增加的可能性。迄今为止,关于肝硬化患者使用PPI与收缩压发展之间的关系的数据是相互矛盾的。虽然一些观察性研究没有发现肝硬化患者使用PPI与SBP发生风险增加之间的关联,但许多其他研究支持这种关联。由于来自病例对照、队列和荟萃分析的结论相互矛盾,我们的目的是对基于电子病历的商业数据库EXPLORYS (IMB-WATSON, Cleveland, Ohio)中的肝硬化患者数据进行回顾性队列分析。我们的目的是评估肝硬化患者使用PPIs与SBP发展风险之间的可能关联,并比较积极使用PPIs的肝硬化患者与未使用PPIs的肝硬化患者之间SBP发展的患病率。方法:对纳入电子医疗记录商业数据库EXPLORYS (IMB-WATSON, Cleveland, Ohio)的肝硬化患者进行回顾性队列分析和图表复习。使用该数据库,审查了2017年12月至2020年期间的记录。纳入的患者年龄在30至79岁之间,经系统化医学临床术语命名法(SNOMED-CT)诊断为肝硬化。经SNOMED-CT诊断为肝硬化的患者被分为两组:第一组包括所有未使用PPIs的肝硬化患者,第二组包括所有在家使用PPIs的肝硬化患者。结果:在我们的分析中,无论是否积极服用PPIs,纳入的肝硬化患者中有1.7%(1860例患者)发生了SBP。在40670名在家接受PPIs治疗的肝硬化患者中,1350名(3.3%)患者发生了SBP。在多变量分析中,使用PPI是肝硬化患者SBP的最强预测因子(优势比(OR) = 4.24;95%可信区间(CI): 3.83 - 4.7, P值< 0.0001),服用PPIs的肝硬化患者发生SBP的可能性比未服用PPIs的患者高4.24。此外,PPI的使用、静脉曲张出血史、年龄、种族和性别被发现是独立的预测收缩压的因素,其重要性由高到低。结论:我们的回顾性队列分析显示,肝硬化患者使用PPIs是预测收缩压发生的独立危险因素。它巩固了接受这种治疗的肝硬化患者似乎有更高的发生收缩压的风险的论点。在新出现的证据表明PPIs可能对肝硬化患者造成健康风险的背景下,需要进一步的研究来解决目前这一主张的支持者和反对者之间的争论。此外,未来的研究可能有助于阐明肝硬化患者发生收缩压与使用PPIs的类型、剂量和持续时间之间的关系。我们建议除非有明确指示,否则肝硬化患者应避免或谨慎使用PPI治疗。
{"title":"Proton Pump Inhibitors Use and Increased Risk of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Retrospective Cohort Analysis.","authors":"Loai Dahabra,&nbsp;Malek Kreidieh,&nbsp;Mohammad Abureesh,&nbsp;Ahmad Abou Yassine,&nbsp;Liliane Deeb","doi":"10.14740/gr1545","DOIUrl":"https://doi.org/10.14740/gr1545","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Since their introduction in the early 1980s, proton pump inhibitors (PPIs) have been used worldwide for a broad range of indications. Unfortunately, however, PPIs have become overly prescribed by healthcare providers, sometimes in the absence of clear indications. Although PPIs were initially presumed to have an excellent safety profile, emerging studies have shed light on the association between their long-term use and a myriad of side effects, including the possibility of an increased risk of spontaneous bacterial peritonitis (SBP). Data available to date regarding the association between PPI use and SBP development in cirrhotic patients is conflicting. While some observational studies provide no association between PPI use in cirrhotic patients and an increased risk of SBP development, many others support this association. As a result of the conflicting conclusions from case controls, cohorts, and meta-analyses, we aimed to carry out this retrospective cohort analysis of data from cirrhotic patients included in the electronic medical record-based commercial database, EXPLORYS (IMB-WATSON, Cleveland, Ohio). Our aim was to evaluate for a possible association between PPIs use and the risk of SBP development in cirrhotic patients and to compare the prevalence of SBP development between cirrhotic patients who were actively using PPIs and those who were not.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective cohort analysis with chart review was conducted on patients with cirrhosis who were included in the electronic medical record-based commercial database, EXPLORYS (IMB-WATSON, Cleveland, Ohio). Using this database, records were reviewed between December 2017 and 2020. Included patients were adults aged 30 to 79 years with a Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT) diagnosis of liver cirrhosis. Included patients with a SNOMED-CT diagnosis of liver cirrhosis were divided into two groups: the first group included all cirrhotic patients who did not use PPIs and the second group included all cirrhotic patients who were on PPIs at home.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In our analysis, SBP occurred in 1.7% (1,860 patients) of the included cirrhotic patients whether they were actively taking PPIs or not. Among the 40,670 cirrhotic patients who were on PPIs at home, 1,350 (3.3%) patients developed SBP. On multivariate analysis, PPI use was the strongest predictor for SBP in cirrhotic patients (odds ratio (OR) = 4.24; 95% confidence interval (CI): 3.83 - 4.7, P value &lt; 0.0001), with cirrhotic patients taking PPIs being 4.24 more likely to develop SBP than those not on PPIs. In addition, PPI use, history of bleeding varices, age, race, and gender were found to be independent predicting factors for SBP, in descending order of importance.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Our retrospective cohort analysis has shown that the use of PPIs in patients with liver cirrhosis is an independent predicting risk fac","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 4","pages":"180-187"},"PeriodicalIF":1.5,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/f7/gr-15-180.PMC9451581.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40372605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Early Colonoscopy in Hospitalized Patients With Acute Lower Gastrointestinal Bleeding: A Nationwide Analysis. 急性下消化道出血住院患者的早期结肠镜检查:一项全国性分析。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-08-01 Epub Date: 2022-08-23 DOI: 10.14740/gr1536
Kuldeepsinh P Atodaria, Samyak Dhruv, Joseph M Bruno, Brisha Bhikadiya, Shravya R Ginnaram, Shreeja Shah

Background: Performing colonoscopy within 24 h of presentation to the hospital is the accepted standard of care for patients with an acute lower gastrointestinal bleed (LGIB). Previous studies have failed to demonstrate the benefit of early colonoscopy (EC) on mortality. In this study, we wanted to see if there was a change in inpatient deaths (primary outcome), length of stay (LOS), and hospitalization charges (TOTCHG) (secondary outcomes) with EC compared to previous studies.

Methods: Adults diagnosed with LGIB were identified using the International Classification of Disease 10th Revision codes from the National Inpatient Sample database for 2016 to 2019. EC was defined as the procedure performed within 24 h of hospitalization. Delayed colonoscopy (DC) was defined as a procedure performed after 24 h of presentation. The patient population was divided into EC and DC groups, and the effects of several covariates on outcomes were measured using binary logistic and multivariate regression analysis. Inverse probability treatment weighting (IPTW) was performed to adjust for confounding covariates.

Results: There were 1,549,065 cases diagnosed with LGIB, of which 285,165 cases (18.4%) received a colonoscopy. A total of 107,045 (6.9%) patients received early colonoscopies. EC was associated with decreased inpatient deaths (0.9% in EC, and 1.4% in DC, P < 0.001). However, upon IPTW, this difference was not present. EC was associated with a decreased LOS (median 3 days vs. 5 days, P < 0.001) and TOTCHG (median $32,037 vs. $44,092, P < 0.001). Weekend admissions (WA) were associated with fewer EC (31.6% in WA, and 39.5% in non-WA, P < 0.001). WA did not affect inpatient deaths.

Conclusions: EC was not associated with decreased inpatient deaths. There was no difference in endoscopic interventions in both EC and DC groups. The difference in inpatient deaths observed between the two groups was not evident upon adjusting the results for confounders. EC was associated with a decreased LOS, and TOTCHG in patients with LGIB.

背景:在入院24小时内进行结肠镜检查是急性下消化道出血(LGIB)患者公认的护理标准。先前的研究未能证明早期结肠镜检查(EC)对死亡率的好处。在这项研究中,我们想看看与以前的研究相比,EC在住院患者死亡(主要结局)、住院时间(LOS)和住院费用(次要结局)方面是否有变化。方法:使用2016 - 2019年国家住院患者样本数据库中的国际疾病分类第10次修订代码对诊断为LGIB的成年人进行鉴定。EC定义为住院后24小时内进行的手术。延迟结肠镜检查(DC)被定义为24小时后进行的手术。将患者人群分为EC组和DC组,采用二元logistic和多元回归分析测量多个协变量对结果的影响。采用逆概率处理加权(IPTW)来调整混杂协变量。结果:诊断为LGIB的1549065例,其中285165例(18.4%)接受了结肠镜检查。107,045例(6.9%)患者接受了早期结肠镜检查。EC与住院死亡率降低相关(EC为0.9%,DC为1.4%,P < 0.001)。然而,在IPTW时,这种差异不存在。EC与LOS(中位3天vs. 5天,P < 0.001)和TOTCHG(中位32,037美元vs. 44,092美元,P < 0.001)降低相关。周末入院(WA)与较少的EC相关(WA为31.6%,非WA为39.5%,P < 0.001)。睡眠不足对住院病人死亡没有影响。结论:EC与住院死亡率的降低无关。内镜干预在EC组和DC组中没有差异。在调整混杂因素的结果后,两组之间观察到的住院患者死亡的差异并不明显。EC与LGIB患者的LOS和TOTCHG降低有关。
{"title":"Early Colonoscopy in Hospitalized Patients With Acute Lower Gastrointestinal Bleeding: A Nationwide Analysis.","authors":"Kuldeepsinh P Atodaria,&nbsp;Samyak Dhruv,&nbsp;Joseph M Bruno,&nbsp;Brisha Bhikadiya,&nbsp;Shravya R Ginnaram,&nbsp;Shreeja Shah","doi":"10.14740/gr1536","DOIUrl":"https://doi.org/10.14740/gr1536","url":null,"abstract":"<p><strong>Background: </strong>Performing colonoscopy within 24 h of presentation to the hospital is the accepted standard of care for patients with an acute lower gastrointestinal bleed (LGIB). Previous studies have failed to demonstrate the benefit of early colonoscopy (EC) on mortality. In this study, we wanted to see if there was a change in inpatient deaths (primary outcome), length of stay (LOS), and hospitalization charges (TOTCHG) (secondary outcomes) with EC compared to previous studies.</p><p><strong>Methods: </strong>Adults diagnosed with LGIB were identified using the International Classification of Disease 10th Revision codes from the National Inpatient Sample database for 2016 to 2019. EC was defined as the procedure performed within 24 h of hospitalization. Delayed colonoscopy (DC) was defined as a procedure performed after 24 h of presentation. The patient population was divided into EC and DC groups, and the effects of several covariates on outcomes were measured using binary logistic and multivariate regression analysis. Inverse probability treatment weighting (IPTW) was performed to adjust for confounding covariates.</p><p><strong>Results: </strong>There were 1,549,065 cases diagnosed with LGIB, of which 285,165 cases (18.4%) received a colonoscopy. A total of 107,045 (6.9%) patients received early colonoscopies. EC was associated with decreased inpatient deaths (0.9% in EC, and 1.4% in DC, P < 0.001). However, upon IPTW, this difference was not present. EC was associated with a decreased LOS (median 3 days vs. 5 days, P < 0.001) and TOTCHG (median $32,037 vs. $44,092, P < 0.001). Weekend admissions (WA) were associated with fewer EC (31.6% in WA, and 39.5% in non-WA, P < 0.001). WA did not affect inpatient deaths.</p><p><strong>Conclusions: </strong>EC was not associated with decreased inpatient deaths. There was no difference in endoscopic interventions in both EC and DC groups. The difference in inpatient deaths observed between the two groups was not evident upon adjusting the results for confounders. EC was associated with a decreased LOS, and TOTCHG in patients with LGIB.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 4","pages":"162-172"},"PeriodicalIF":1.5,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/36/gr-15-162.PMC9451577.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40372608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends of Alcohol Withdrawal Delirium in the Last Decade: Analysis of the Nationwide Inpatient Sample. 近十年来酒精戒断性谵妄的趋势:全国住院患者样本分析。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-08-01 Epub Date: 2022-08-23 DOI: 10.14740/gr1550
Hisham Laswi, Bashar Attar, Robert Kwei, Pius Ojemolon, Ebehiwele Ebhohon, Hafeez Shaka

Background: Alcohol use disorder, high-risk drinking, and emergency visits for acute and chronic complications of alcohol use have been increasing in the USA recently. Approximately half of patients with alcohol use disorder experience alcohol withdrawal when they reduce or stop drinking. Though alcohol withdrawal is usually mild, 20% of patients experience more severe manifestations such as hallucinations, seizures, and delirium. In this study, we utilized the Nationwide Inpatient Sample to examine the trends of alcohol withdrawal delirium (AWD) in the period 2010 - 2019.

Methods: This was a retrospective longitudinal trends study involving hospitalizations with AWD in the USA from 2010 to 2019. We searched the databases for hospitalizations using the International Classification of Diseases (ICD) codes (291.0 and F10231). We involved all hospitalizations complicated by AWD and hospitalizations with AWD as the principal diagnosis for admission. We excluded hospitalizations involving patients under the age of 18. We calculated the crude admission rate and the incidence of AWD per million adult hospitalizations during each calendar year. In addition, we analyzed trends of inpatient mortality, length of stay (LOS), and total hospital charges (THC).

Results: The incidence of AWD per million hospitalizations increased from 2,671.8 in 2010 to 3,405.6 in 2019, with an annual percentage change (APC) of 3.1% (P < 0.001). Similarly, AWD admission rate per million hospitalizations increased from 1,030.3 in 2010 to 1,556.0 in 2019, with an average APC of 5.0% (P < 0.001). There were statistically significant trends of increasing inpatient mortality, THC, and LOS over the studied period. In general, female gender, younger age, and Black race were associated with better clinical outcomes.

Conclusions: Our study showed an increase in the incidence and admission rates of AWD. Mortality, LOS, and THC increased over the studied period. Younger age, female gender, and Black race were associated with better clinical outcomes.

背景:最近在美国,酒精使用障碍、高风险饮酒和因酒精使用急性和慢性并发症而急诊就诊的人数不断增加。大约一半的酒精使用障碍患者在减少或停止饮酒后会出现酒精戒断。虽然酒精戒断通常是轻微的,但20%的患者会出现更严重的症状,如幻觉、癫痫发作和谵妄。在本研究中,我们利用全国住院患者样本来研究2010 - 2019年期间酒精戒断性谵妄(AWD)的趋势。方法:这是一项回顾性纵向趋势研究,涉及2010年至2019年美国因AWD住院的患者。我们使用国际疾病分类(ICD)代码(291.0和F10231)在数据库中检索住院病例。我们纳入了所有因AWD合并住院以及以AWD为主要入院诊断的住院情况。我们排除了18岁以下患者的住院情况。我们计算了每个日历年的粗入院率和每百万成人住院的AWD发生率。此外,我们还分析了住院死亡率、住院时间(LOS)和医院总收费(THC)的趋势。结果:每百万住院患者AWD发生率从2010年的2671.8例上升至2019年的3405.6例,年变化百分比(APC)为3.1% (P < 0.001)。同样,每百万住院患者的AWD住院率从2010年的1,030.3上升到2019年的1,556.0,平均APC为5.0% (P < 0.001)。在研究期间,住院病人死亡率、THC和LOS的增加趋势有统计学意义。一般来说,女性、年轻和黑人种族与更好的临床结果相关。结论:我们的研究显示AWD的发病率和住院率增加。死亡率、LOS和THC在研究期间有所增加。较年轻的年龄、女性和黑人种族与较好的临床结果相关。
{"title":"Trends of Alcohol Withdrawal Delirium in the Last Decade: Analysis of the Nationwide Inpatient Sample.","authors":"Hisham Laswi,&nbsp;Bashar Attar,&nbsp;Robert Kwei,&nbsp;Pius Ojemolon,&nbsp;Ebehiwele Ebhohon,&nbsp;Hafeez Shaka","doi":"10.14740/gr1550","DOIUrl":"https://doi.org/10.14740/gr1550","url":null,"abstract":"<p><strong>Background: </strong>Alcohol use disorder, high-risk drinking, and emergency visits for acute and chronic complications of alcohol use have been increasing in the USA recently. Approximately half of patients with alcohol use disorder experience alcohol withdrawal when they reduce or stop drinking. Though alcohol withdrawal is usually mild, 20% of patients experience more severe manifestations such as hallucinations, seizures, and delirium. In this study, we utilized the Nationwide Inpatient Sample to examine the trends of alcohol withdrawal delirium (AWD) in the period 2010 - 2019.</p><p><strong>Methods: </strong>This was a retrospective longitudinal trends study involving hospitalizations with AWD in the USA from 2010 to 2019. We searched the databases for hospitalizations using the International Classification of Diseases (ICD) codes (291.0 and F10231). We involved all hospitalizations complicated by AWD and hospitalizations with AWD as the principal diagnosis for admission. We excluded hospitalizations involving patients under the age of 18. We calculated the crude admission rate and the incidence of AWD per million adult hospitalizations during each calendar year. In addition, we analyzed trends of inpatient mortality, length of stay (LOS), and total hospital charges (THC).</p><p><strong>Results: </strong>The incidence of AWD per million hospitalizations increased from 2,671.8 in 2010 to 3,405.6 in 2019, with an annual percentage change (APC) of 3.1% (P < 0.001). Similarly, AWD admission rate per million hospitalizations increased from 1,030.3 in 2010 to 1,556.0 in 2019, with an average APC of 5.0% (P < 0.001). There were statistically significant trends of increasing inpatient mortality, THC, and LOS over the studied period. In general, female gender, younger age, and Black race were associated with better clinical outcomes.</p><p><strong>Conclusions: </strong>Our study showed an increase in the incidence and admission rates of AWD. Mortality, LOS, and THC increased over the studied period. Younger age, female gender, and Black race were associated with better clinical outcomes.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 4","pages":"207-216"},"PeriodicalIF":1.5,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/86/gr-15-207.PMC9451584.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40374862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Safety of the Re-Opening of an Academic Medical Center Outpatient Endoscopy Unit During the COVID-19 Pandemic. 新冠肺炎大流行期间学术医疗中心门诊内窥镜室重新开放的安全性
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-08-01 Epub Date: 2022-08-23 DOI: 10.14740/gr1551
Scott Manski, Christopher J Schmoyer, Alice Pang, Joshua Lieberman, Micaela Gernhardt, Elizabeth Conn, Neveda Murugesan, Alexandra Leto, Ryan Erwin, Taylor Kavanagh, Mitchell Conn

Background: The coronavirus disease 2019 (COVID-19) pandemic has spread globally leading to over 3,700,000 deaths. As COVID-19 cases stabilized, the re-opening of endoscopy centers potentially exposed patients and healthcare workers to viral infection. This study aims to determine risk of COVID-19 exposure among patients undergoing outpatient endoscopies in a tertiary care setting during the COVID-19 pandemic.

Methods: Patients undergoing outpatient endoscopy were contacted post-procedure for any new COVID-19 symptoms or COVID-19 test results. Patient experiences and perception of personal safety were also determined.

Results: Of the 1,584 patients who completed elective endoscopy, 996 (62.9%) completed the survey. Two patients were diagnosed with COVID-19 within 14 days of procedure. The majority (99.7%) felt safe during their procedure and apprehension regarding endoscopy decreased over time.

Conclusion: Thus, the risk of COVID-19 transmission during outpatient endoscopy is extremely low when following recommended society guidelines. Patients felt safe during the procedure and experienced less fear of exposure over time.

背景:2019年冠状病毒病(COVID-19)大流行已在全球蔓延,导致370多万人死亡。随着COVID-19病例的稳定,重新开放的内窥镜检查中心可能使患者和医护人员暴露于病毒感染之中。本研究旨在确定COVID-19大流行期间在三级医疗机构接受门诊内窥镜检查的患者暴露于COVID-19的风险。方法:随访门诊内窥镜检查患者术后有无新发症状或检测结果。患者体验和个人安全感知也被确定。结果:在1584例完成择期内镜检查的患者中,996例(62.9%)完成了调查。两名患者在手术后14天内被诊断为COVID-19。大多数患者(99.7%)在手术过程中感到安全,对内窥镜检查的担忧随着时间的推移而减少。结论:因此,在遵循社会推荐指南的情况下,门诊内镜检查期间COVID-19传播的风险极低。患者在手术过程中感到安全,并且随着时间的推移,对暴露的恐惧减少了。
{"title":"The Safety of the Re-Opening of an Academic Medical Center Outpatient Endoscopy Unit During the COVID-19 Pandemic.","authors":"Scott Manski,&nbsp;Christopher J Schmoyer,&nbsp;Alice Pang,&nbsp;Joshua Lieberman,&nbsp;Micaela Gernhardt,&nbsp;Elizabeth Conn,&nbsp;Neveda Murugesan,&nbsp;Alexandra Leto,&nbsp;Ryan Erwin,&nbsp;Taylor Kavanagh,&nbsp;Mitchell Conn","doi":"10.14740/gr1551","DOIUrl":"https://doi.org/10.14740/gr1551","url":null,"abstract":"<p><strong>Background: </strong>The coronavirus disease 2019 (COVID-19) pandemic has spread globally leading to over 3,700,000 deaths. As COVID-19 cases stabilized, the re-opening of endoscopy centers potentially exposed patients and healthcare workers to viral infection. This study aims to determine risk of COVID-19 exposure among patients undergoing outpatient endoscopies in a tertiary care setting during the COVID-19 pandemic.</p><p><strong>Methods: </strong>Patients undergoing outpatient endoscopy were contacted post-procedure for any new COVID-19 symptoms or COVID-19 test results. Patient experiences and perception of personal safety were also determined.</p><p><strong>Results: </strong>Of the 1,584 patients who completed elective endoscopy, 996 (62.9%) completed the survey. Two patients were diagnosed with COVID-19 within 14 days of procedure. The majority (99.7%) felt safe during their procedure and apprehension regarding endoscopy decreased over time.</p><p><strong>Conclusion: </strong>Thus, the risk of COVID-19 transmission during outpatient endoscopy is extremely low when following recommended society guidelines. Patients felt safe during the procedure and experienced less fear of exposure over time.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 4","pages":"200-206"},"PeriodicalIF":1.5,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/af/c5/gr-15-200.PMC9451579.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40372604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Association Between Gastroesophageal Reflux Disease and Non-Small Cell Lung Cancer: A Retrospective Case-Control Study. 胃食管反流病与非小细胞肺癌的相关性:一项回顾性病例对照研究
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-08-01 Epub Date: 2022-07-12 DOI: 10.14740/gr1537
Shivantha Amarnath, Adam Starr, Divya Chukkalore, Ahmed Elfiky, Mohammad Abureesh, Anum Aqsa, Chetan Singh, Chanudi Weerasinghe, Dhineshreddy Gurala, Seleshi Demissie, Liliane Deeb, Terenig Terjanian

Background: Lung cancer is a leading cause of mortality in the USA. Non-small cell lung cancer (NSCLC) contributes to 85% of all lung cancers. It is the most prevalent subtype amongst non-smokers, and its incidence has risen in the last 20 years. In addition, gastroesophageal reflux disease (GERD) has been associated with several lung pathologies, namely idiopathic pulmonary fibrosis and asthma. We aimed to investigate the association between GERD and NSCLC by performing a retrospective, multicenter, case-control study. This is the first study of this nature to be carried out in the USA.

Methods: Data were retrieved from 17 Northwell health care facilities in the New York area between the years 2010 and 2018. Inclusion criteria were patients > 18 years of age with NSCLC (large cell, adenocarcinoma, and squamous cell). They were appropriately matched with controls based on age, gender, weight, comorbidities, and medication use. Our exposure group had a diagnosis of GERD based on the International Classification of Diseases, Ninth/10th Revision (ICD 9/10) codes and endoscopic, in addition to histological evidence if present. We excluded patients with secondary lung cancers, esophageal adenocarcinoma, other primary malignancies, Barrett's esophagus, and smokers. Logistic regression was conducted to determine the adjusted odds ratio (OR) and corresponding 95% confidence interval (CI) for the association between NSCLC and GERD.

Results: A total of 1,083 subjects were included in our study: 543 (50%) patients were diagnosed with NSCLC. In this population, GERD was twice as prevalent compared to controls (20.4% vs. 11.6%, P < 0.001). Multivariate analysis demonstrated that GERD was associated with a higher risk of NSCLC compared to matched controls (OR = 1.86, 95% CI = 1.26 - 2.73). In addition, GERD patients treated with either antihistamines or proton pump inhibitors did not demonstrate an overall reduced risk of NSCLC (OR = 1.01, 95% CI = 0.48 - 2.12).

Conclusions: Our study demonstrates that GERD is associated with a higher risk of NSCLC, irrespective of GERD treatment. We postulate that GERD patients suffer from chronic micro-aspirations leading to a prolonged inflammatory state within the lung parenchyma, triggering specific proliferative signaling pathways that may lead to malignant transformation.

背景:肺癌是美国死亡的主要原因。非小细胞肺癌(NSCLC)占所有肺癌的85%。它是非吸烟者中最普遍的亚型,其发病率在过去20年中有所上升。此外,胃食管反流病(GERD)与几种肺部病变有关,即特发性肺纤维化和哮喘。我们旨在通过一项回顾性、多中心、病例对照研究来调查GERD与NSCLC之间的关系。这是在美国进行的第一次这种性质的研究。方法:检索2010年至2018年纽约地区17家诺斯韦尔卫生保健机构的数据。纳入标准为> 18岁的非小细胞肺癌(大细胞、腺癌和鳞状细胞)患者。他们根据年龄、性别、体重、合并症和药物使用情况与对照组适当匹配。我们暴露组根据国际疾病分类,第九/第十版(ICD 9/10)代码和内镜诊断为GERD,如果有组织学证据的话。我们排除了继发性肺癌、食管腺癌、其他原发性恶性肿瘤、巴雷特食管和吸烟者。采用Logistic回归来确定NSCLC与GERD之间的校正优势比(OR)和相应的95%可信区间(CI)。结果:我们的研究共纳入1083名受试者,其中543名(50%)患者被诊断为NSCLC。在该人群中,GERD的患病率是对照组的两倍(20.4%比11.6%,P < 0.001)。多因素分析显示,与匹配对照组相比,GERD与NSCLC的高风险相关(OR = 1.86, 95% CI = 1.26 - 2.73)。此外,接受抗组胺药或质子泵抑制剂治疗的GERD患者并未显示出NSCLC的总体风险降低(or = 1.01, 95% CI = 0.48 - 2.12)。结论:我们的研究表明,与GERD治疗无关,GERD与NSCLC的高风险相关。我们假设GERD患者患有慢性微渴望,导致肺实质内长期炎症状态,触发特异性增殖信号通路,可能导致恶性转化。
{"title":"The Association Between Gastroesophageal Reflux Disease and Non-Small Cell Lung Cancer: A Retrospective Case-Control Study.","authors":"Shivantha Amarnath,&nbsp;Adam Starr,&nbsp;Divya Chukkalore,&nbsp;Ahmed Elfiky,&nbsp;Mohammad Abureesh,&nbsp;Anum Aqsa,&nbsp;Chetan Singh,&nbsp;Chanudi Weerasinghe,&nbsp;Dhineshreddy Gurala,&nbsp;Seleshi Demissie,&nbsp;Liliane Deeb,&nbsp;Terenig Terjanian","doi":"10.14740/gr1537","DOIUrl":"https://doi.org/10.14740/gr1537","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer is a leading cause of mortality in the USA. Non-small cell lung cancer (NSCLC) contributes to 85% of all lung cancers. It is the most prevalent subtype amongst non-smokers, and its incidence has risen in the last 20 years. In addition, gastroesophageal reflux disease (GERD) has been associated with several lung pathologies, namely idiopathic pulmonary fibrosis and asthma. We aimed to investigate the association between GERD and NSCLC by performing a retrospective, multicenter, case-control study. This is the first study of this nature to be carried out in the USA.</p><p><strong>Methods: </strong>Data were retrieved from 17 Northwell health care facilities in the New York area between the years 2010 and 2018. Inclusion criteria were patients > 18 years of age with NSCLC (large cell, adenocarcinoma, and squamous cell). They were appropriately matched with controls based on age, gender, weight, comorbidities, and medication use. Our exposure group had a diagnosis of GERD based on the International Classification of Diseases, Ninth/10th Revision (ICD 9/10) codes and endoscopic, in addition to histological evidence if present. We excluded patients with secondary lung cancers, esophageal adenocarcinoma, other primary malignancies, Barrett's esophagus, and smokers. Logistic regression was conducted to determine the adjusted odds ratio (OR) and corresponding 95% confidence interval (CI) for the association between NSCLC and GERD.</p><p><strong>Results: </strong>A total of 1,083 subjects were included in our study: 543 (50%) patients were diagnosed with NSCLC. In this population, GERD was twice as prevalent compared to controls (20.4% vs. 11.6%, P < 0.001). Multivariate analysis demonstrated that GERD was associated with a higher risk of NSCLC compared to matched controls (OR = 1.86, 95% CI = 1.26 - 2.73). In addition, GERD patients treated with either antihistamines or proton pump inhibitors did not demonstrate an overall reduced risk of NSCLC (OR = 1.01, 95% CI = 0.48 - 2.12).</p><p><strong>Conclusions: </strong>Our study demonstrates that GERD is associated with a higher risk of NSCLC, irrespective of GERD treatment. We postulate that GERD patients suffer from chronic micro-aspirations leading to a prolonged inflammatory state within the lung parenchyma, triggering specific proliferative signaling pathways that may lead to malignant transformation.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 4","pages":"173-179"},"PeriodicalIF":1.5,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/e2/gr-15-173.PMC9451582.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40372607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Readmissions After Biliary Acute Pancreatitis: Analysis of the Nationwide Readmissions Database. 胆道性急性胰腺炎再入院:全国再入院数据库分析。
IF 1.5 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2022-08-01 Epub Date: 2022-08-23 DOI: 10.14740/gr1548
Hisham Laswi, Bashar Attar, Robert Kwei, Michelle Ishaya, Pius Ojemolon, Bashar Natour, Mohammad Darweesh, Hafeez Shaka

Background: Acute pancreatitis is a common inflammatory condition that involves the pancreas. Gallstones and alcohol are the most common etiologies in the USA. Cholecystectomy is the cornerstone procedure in the management of biliary acute pancreatitis (BAP). In this study, we examined the causes and predictors of readmissions following BAP based on the procedure performed.

Methods: Using the Nationwide Readmissions Database (NRD) and the International Classification of Diseases, Tenth Revision, Clinical Modification/Procedure Coding System (ICD10-CM/PCS), we retrospectively studied BAP hospitalizations (2016 - 2018). The first hospitalization within the year was marked as index hospitalization. Index hospitalizations were categorized based on whether an endoscopic retrograde cholangiopancreatography (ERCP) and/or a cholecystectomy was performed into no procedure group, ERCP group, cholecystectomy group, and both procedures group. We subsequently identified readmissions within 30 days. Using this categorization, we studied reasons, rates, and predictors of readmissions.

Results: A total of 127,318 index hospitalizations were included. The cholecystectomy group constituted the largest share of this cohort (43.5%). Using the no procedure group as a reference, analysis of the outcomes showed that the cholecystectomy group had the lowest inpatient mortality (adjusted odds ratio (aOR): 0.18, P < 0.001), while both procedures group had the highest total hospital charges (adjusted mean difference (aMD): 42,249, P < 0.001). Acute pancreatitis without necrosis or infection was the most frequent principal diagnosis for readmission (18.7%). Analysis of readmission predictors showed that both procedures group had the lowest risk for readmission (adjusted hazard ratio (aHR): 0.40, P < 0.001). Females were less likely to be readmitted compared to males (aHR: 0.82, P < 0.001) and elderly were less likely to be readmitted compared to young adults (aHR: 0.82, P < 0.001). Patients discharged against medical advice were more likely to be readmitted (aHR: 1.76, P < 0.001).

Conclusion: Undergoing both ERCP and cholecystectomy for BAP resulted in significantly higher hospital charges with no additional mortality benefit. However, it decreased the readmission risk significantly. Acute pancreatitis without necrosis or infection was the most frequent reason for readmissions.

背景:急性胰腺炎是一种常见的累及胰腺的炎症。胆结石和酒精是美国最常见的病因。胆囊切除术是胆源性急性胰腺炎(BAP)治疗的基础手术。在这项研究中,我们根据所执行的程序检查了BAP后再入院的原因和预测因素。方法:利用全国再入院数据库(NRD)和《国际疾病分类第十版临床修改/程序编码系统》(ICD10-CM/PCS),回顾性研究2016 - 2018年BAP住院情况。年内首次住院作为指标住院。根据是否行内窥镜逆行胰胆管造影(ERCP)和/或胆囊切除术将住院指数分为无手术组、ERCP组、胆囊切除术组和两种手术组。我们随后在30天内确定了再入院人数。使用这种分类,我们研究了再入院的原因、比率和预测因素。结果:共纳入指标住院127318例。胆囊切除术组占该队列的最大份额(43.5%)。以未手术组为对照,结果分析显示,胆囊切除术组住院死亡率最低(调整优势比(aOR): 0.18, P < 0.001),两种手术组住院总费用最高(调整平均差(aMD): 42,249, P < 0.001)。无坏死或感染的急性胰腺炎是再入院最常见的主要诊断(18.7%)。再入院预测因素分析显示,两组再入院风险最低(调整风险比(aHR): 0.40, P < 0.001)。女性再入院的可能性低于男性(aHR: 0.82, P < 0.001),老年人再入院的可能性低于年轻人(aHR: 0.82, P < 0.001)。不遵医嘱出院的患者再次入院的可能性更大(aHR: 1.76, P < 0.001)。结论:接受ERCP和胆囊切除术治疗BAP的住院费用明显增加,没有额外的死亡率优势。然而,它显著降低了再入院风险。无坏死或感染的急性胰腺炎是再入院最常见的原因。
{"title":"Readmissions After Biliary Acute Pancreatitis: Analysis of the Nationwide Readmissions Database.","authors":"Hisham Laswi,&nbsp;Bashar Attar,&nbsp;Robert Kwei,&nbsp;Michelle Ishaya,&nbsp;Pius Ojemolon,&nbsp;Bashar Natour,&nbsp;Mohammad Darweesh,&nbsp;Hafeez Shaka","doi":"10.14740/gr1548","DOIUrl":"https://doi.org/10.14740/gr1548","url":null,"abstract":"<p><strong>Background: </strong>Acute pancreatitis is a common inflammatory condition that involves the pancreas. Gallstones and alcohol are the most common etiologies in the USA. Cholecystectomy is the cornerstone procedure in the management of biliary acute pancreatitis (BAP). In this study, we examined the causes and predictors of readmissions following BAP based on the procedure performed.</p><p><strong>Methods: </strong>Using the Nationwide Readmissions Database (NRD) and the International Classification of Diseases, Tenth Revision, Clinical Modification/Procedure Coding System (ICD10-CM/PCS), we retrospectively studied BAP hospitalizations (2016 - 2018). The first hospitalization within the year was marked as index hospitalization. Index hospitalizations were categorized based on whether an endoscopic retrograde cholangiopancreatography (ERCP) and/or a cholecystectomy was performed into no procedure group, ERCP group, cholecystectomy group, and both procedures group. We subsequently identified readmissions within 30 days. Using this categorization, we studied reasons, rates, and predictors of readmissions.</p><p><strong>Results: </strong>A total of 127,318 index hospitalizations were included. The cholecystectomy group constituted the largest share of this cohort (43.5%). Using the no procedure group as a reference, analysis of the outcomes showed that the cholecystectomy group had the lowest inpatient mortality (adjusted odds ratio (aOR): 0.18, P < 0.001), while both procedures group had the highest total hospital charges (adjusted mean difference (aMD): 42,249, P < 0.001). Acute pancreatitis without necrosis or infection was the most frequent principal diagnosis for readmission (18.7%). Analysis of readmission predictors showed that both procedures group had the lowest risk for readmission (adjusted hazard ratio (aHR): 0.40, P < 0.001). Females were less likely to be readmitted compared to males (aHR: 0.82, P < 0.001) and elderly were less likely to be readmitted compared to young adults (aHR: 0.82, P < 0.001). Patients discharged against medical advice were more likely to be readmitted (aHR: 1.76, P < 0.001).</p><p><strong>Conclusion: </strong>Undergoing both ERCP and cholecystectomy for BAP resulted in significantly higher hospital charges with no additional mortality benefit. However, it decreased the readmission risk significantly. Acute pancreatitis without necrosis or infection was the most frequent reason for readmissions.</p>","PeriodicalId":12461,"journal":{"name":"Gastroenterology Research","volume":"15 4","pages":"188-199"},"PeriodicalIF":1.5,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/02/gr-15-188.PMC9451580.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40372609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Gastroenterology Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1